Sensei keeps its eye on VISTA
The micro cap promises data this year, but its peer Kineta winds down a VISTA trial.
Regeneron works to secure fianlimab
A just revealed phase 3 trial will apparently pit a fixed-dose combo head to head against Opdualag.
